OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction
John W. Ostrominski, Muthiah Vaduganathan
The American Journal of Medicine (2023) Vol. 137, Iss. 2, pp. S9-S24
Closed Access | Times Cited: 7
John W. Ostrominski, Muthiah Vaduganathan
The American Journal of Medicine (2023) Vol. 137, Iss. 2, pp. S9-S24
Closed Access | Times Cited: 7
Showing 7 citing articles:
Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1–STING axis
Ying Shi, Lili Zhao, Jing Wang, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Ying Shi, Lili Zhao, Jing Wang, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications
Xiaohui Duan, Xiaomeng Zhang, Bao Sun
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access
Xiaohui Duan, Xiaomeng Zhang, Bao Sun
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
John W. Ostrominski, Muthiah Vaduganathan, Senthil Selvaraj, et al.
Circulation (2023) Vol. 148, Iss. 24, pp. 1945-1957
Closed Access | Times Cited: 8
John W. Ostrominski, Muthiah Vaduganathan, Senthil Selvaraj, et al.
Circulation (2023) Vol. 148, Iss. 24, pp. 1945-1957
Closed Access | Times Cited: 8
Sodium glucose transporter 2 inhibitors: Will these drugs benefit non‐diabetic veterinary patients with cardiac and kidney diseases?
Jonathan Elliott, Mark A. Oyama
Journal of Veterinary Pharmacology and Therapeutics (2024)
Open Access | Times Cited: 1
Jonathan Elliott, Mark A. Oyama
Journal of Veterinary Pharmacology and Therapeutics (2024)
Open Access | Times Cited: 1
Benefícios do Inibidor do Cotransportador de Sódio-Glicose 2 (SGLT2) no tratamento da Insuficiência Cardíaca com fração de ejeção reduzida
Camila Martins Palmeira de Oliveira, Ana Luiza dos Santos Fantoni, Isabella Lugon-Moulin Maraboti, et al.
Brazilian Journal of Health Review (2024) Vol. 7, Iss. 3, pp. e70329-e70329
Open Access
Camila Martins Palmeira de Oliveira, Ana Luiza dos Santos Fantoni, Isabella Lugon-Moulin Maraboti, et al.
Brazilian Journal of Health Review (2024) Vol. 7, Iss. 3, pp. e70329-e70329
Open Access
Cardio-renal protective effect and safety of sodium-glucose cotransporter 2 inhibitors for chronic kidney disease patients with eGFR < 60 mL/min/1.73 m2: a systematic review and meta-analysis
Yaru Zhang, Junhui Luo, Bingxin Li, et al.
BMC Nephrology (2024) Vol. 25, Iss. 1
Open Access
Yaru Zhang, Junhui Luo, Bingxin Li, et al.
BMC Nephrology (2024) Vol. 25, Iss. 1
Open Access
Impact of Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Exercise‐Induced Pulmonary Hypertension
Taijyu Satoh, Nobuhiro Yaoita, Satoshi Higuchi, et al.
Pulmonary Circulation (2024) Vol. 14, Iss. 4
Open Access
Taijyu Satoh, Nobuhiro Yaoita, Satoshi Higuchi, et al.
Pulmonary Circulation (2024) Vol. 14, Iss. 4
Open Access
